EP4728103A2 - Méthylation de l'adn et expression génique utilisées en tant que déterminants de fragmentation d'adn acellulaire à l'échelle génomique - Google Patents

Méthylation de l'adn et expression génique utilisées en tant que déterminants de fragmentation d'adn acellulaire à l'échelle génomique

Info

Publication number
EP4728103A2
EP4728103A2 EP24826511.8A EP24826511A EP4728103A2 EP 4728103 A2 EP4728103 A2 EP 4728103A2 EP 24826511 A EP24826511 A EP 24826511A EP 4728103 A2 EP4728103 A2 EP 4728103A2
Authority
EP
European Patent Office
Prior art keywords
cfdna
cancer
fragments
fragment
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24826511.8A
Other languages
German (de)
English (en)
Inventor
Victor E. Velculescu
Robert B. SCHARPF
Michael Noe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP4728103A2 publication Critical patent/EP4728103A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N20/00—Machine learning
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Software Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Mathematical Physics (AREA)
  • Computing Systems (AREA)
  • Epidemiology (AREA)

Abstract

L'analyse des extrémités de fragments d'ADN acellulaire (ADNa) chez des patients atteints d'un cancer fournit une liaison directe entre des changements épigénétiques et une fragmentation d'ADNa pour la détection et le traitement non invasifs de maladies de patients.
EP24826511.8A 2023-06-17 2024-06-17 Méthylation de l'adn et expression génique utilisées en tant que déterminants de fragmentation d'adn acellulaire à l'échelle génomique Pending EP4728103A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363521666P 2023-06-17 2023-06-17
PCT/US2024/034360 WO2024263526A2 (fr) 2023-06-17 2024-06-17 Méthylation de l'adn et expression génique utilisées en tant que déterminants de fragmentation d'adn acellulaire à l'échelle génomique

Publications (1)

Publication Number Publication Date
EP4728103A2 true EP4728103A2 (fr) 2026-04-22

Family

ID=93936238

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24826511.8A Pending EP4728103A2 (fr) 2023-06-17 2024-06-17 Méthylation de l'adn et expression génique utilisées en tant que déterminants de fragmentation d'adn acellulaire à l'échelle génomique

Country Status (9)

Country Link
EP (1) EP4728103A2 (fr)
JP (1) JP2026522392A (fr)
KR (1) KR20260025833A (fr)
CN (1) CN121693582A (fr)
AU (1) AU2024312665A1 (fr)
CO (1) CO2026000372A2 (fr)
IL (1) IL325231A (fr)
MX (1) MX2025015209A (fr)
WO (1) WO2024263526A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120279994B (zh) * 2025-03-04 2026-03-27 深圳市海普洛斯生物科技有限公司 一种基于全基因组测序筛选外周血中癌症特异性cfDNA片段特征组合的方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120608151A (zh) * 2018-05-18 2025-09-09 约翰·霍普金斯大学 用于评估和/或治疗癌症的无细胞dna
US20250131982A1 (en) * 2021-12-15 2025-04-24 The Johns Hopkins University Single molecule genome-wide mutation and fragmentation profiles of cell-free dna

Also Published As

Publication number Publication date
CO2026000372A2 (es) 2026-01-23
KR20260025833A (ko) 2026-02-24
WO2024263526A9 (fr) 2025-10-09
AU2024312665A1 (en) 2025-12-18
CN121693582A (zh) 2026-03-17
JP2026522392A (ja) 2026-07-07
WO2024263526A2 (fr) 2024-12-26
WO2024263526A3 (fr) 2025-04-17
IL325231A (en) 2026-02-01
MX2025015209A (es) 2026-05-04

Similar Documents

Publication Publication Date Title
Saleh et al. The biology of ependymomas and emerging novel therapies
Chmielik et al. Heterogeneity of thyroid cancer
Ennishi et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
US20240060141A1 (en) Detection of lung cancer using cell-free dna fragmentation
Musto et al. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Griffith et al. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia
US20250131982A1 (en) Single molecule genome-wide mutation and fragmentation profiles of cell-free dna
Yoon et al. Real-world efficacy of 5-azacytidine as salvage chemotherapy for angioimmunoblastic T-cell lymphoma
US20240141437A1 (en) Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
US20240161868A1 (en) System and method for gene expression and tissue of origin inference from cell-free dna
WO2024263526A2 (fr) Méthylation de l'adn et expression génique utilisées en tant que déterminants de fragmentation d'adn acellulaire à l'échelle génomique
Gagne et al. Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas
KR20250128956A (ko) 무세포 dna 단편화를 사용하는 간암 검출
Nelles et al. Real world molecular characterisation and clonal evolution of acute myeloid leukaemia reveals therapeutic opportunities and challenges
CN116940994A (zh) 使用细胞游离dna片段化检测肺癌
WO2026107389A1 (fr) Paysages chromatiniens et fragmentation de l'adn extracellulaire pour le dépistage du cancer colorectal
Ayass et al. Transcriptome-based treatment for melanoma with brain metastasis: A case report
Colombino et al. Mutational Profiles of Cutaneous Squamous Cell Carcinomas with Different Patterns of Clinical Aggression from Head and Neck District
WO2025213107A2 (fr) Détection et traitement du cancer de l'ovaire
Hurtado et al. EGFR Amplification in a Patient with Glioblastoma: A Case Report and Review of the Literature.
Barbe-Richaud et al. Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommon T751_I759delinsAsp EGFR-mutant lung adenocarcinoma: a case report
Kim et al. Yoo-Na Kim1, Kyunglim Lee1, Eunhyang Park2, Junsik Park1, Yong Jae Lee1, Eun Ji Nam1, Sang Wun Kim1, Sunghoon Kim1, Young Tae Kim1 and Jung-Yun Lee1
CN117321225A (zh) 癌症的靶向疗法
VALGIUSTI et al. EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260114

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR